Nu Skin is rated a buy, trading at low multiples with turnaround prospects tied to India expansion and Prysm iO device launch. NUS’s core MLM business faces structural decline, but new product and ...

Ryan S. Napierski. Thanks, B.G. Good afternoon, everyone. Thanks for joining the call. I am pleased to report that we delivered fourth quarter and 2025 results within our guidance range with a strong ...

Nu Skin Enterprises Inc (NYSE:NUS) reported a 40% increase in stock price for the year, reflecting strong improvement in earnings. The company successfully realigned its business following the ...

Nu Skin Enterprises, Inc. NUS posted fourth-quarter 2025 results, with the top and bottom lines missing the Zacks Consensus Estimate. Earnings and net sales declined year over year. In the fourth ...

Aristotle Capital Boston, LLC, an investment advisor, released its fourth-quarter investor letter for “Small Cap Equity Fund”. A copy of the letter can be downloaded here. U.S. small-cap equities ...

Shares of Nu Skin Enterprises were lower after the company reported lower revenue in the fourth quarter and guided for further declines, despite swinging to a profit. Shares were down 17% at $8.45 in ...

Nu Skin Enterprises reported its fourth-quarter 2025 earnings, revealing a miss on both earnings per share (EPS) and revenue forecasts. Despite this, the company’s stock experienced a 1.57% increase ...

I’m fair-skinned, so a pop of color goes a long way on my cheeks, forehead, or jawline. (I don’t even mess with the bridge of my nose, though the placement works “snatching” wonders for Mila Kunis.) ...

Kelly-Ann Franklin has spent more than two decades in journalism which has helped her build a wide knowledge base of business and personal finance topics. Her goal with editing is to ensure tough ...

The fintech upstart delivered record revenue, rising net income, and solid ROE. Nu is becoming a multiproduct banking platform, not just a digital credit card provider. As it expands, this may bring ...

WASHINGTON - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced today that the U.S. Food and Drug Administration has accepted its Biologics License Application for imsidolimab to treat Generalized ...

Here’s what you’ll learn when you read this story: Your skin has an inner structure called rete ridges, which act as a kind of Velcro, holding the layers together. It’s involved in enabling new cell ...